Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL)

Inclusion Criteria: * Age 18 to 80 years. * Imaging-confirmed anterior-circulation large-vessel occlusion involving the intracranial internal carotid artery, the middle cerebral artery M1 segment, or the proximal M2 segment or a dominant M2 branch. A dominant M2 branch was defined as an M2 branch supplying ≥50% of the middle cerebral artery territory. * Eligible for and planned to undergo endovascular treatment (EVT) within 24 hours according to current clinical practice. * National Institutes of Health Stroke Scale (NIHSS) score ≥6 at baseline. * Alberta Stroke Program Early CT Score (ASPECTS) ≥6 on baseline noncontrast CT. * Pre-stroke modified Rankin Scale (mRS) score of 0 to 1. * Provision of written informed consent by the participant or the participant's legally authorized representative. Exclusion Criteria: * Evidence of intracranial hemorrhagic disease on head CT, including hemorrhagic stroke, epidural hematoma, subdural hematoma, intraventricular hemorrhage, or subarachnoid hemorrhage. * History of congenital or acquired bleeding disorders, coagulation factor deficiency, thrombocytopenic disorders, or other clinically significant hemorrhagic conditions. * Vascular anatomy expected to preclude successful endovascular treatment because of excessive tortuosity or other technical reasons. * Known allergy to iodinated contrast agents. * Pregnant or breastfeeding women, or women planning pregnancy during the study period or within 90 days after enrollment. * Known hyper…